A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib
Lung Cancer: Targets and Therapy · 2022-11 · Volume 13 · 75-80
DOI: 10.2147/lctt.s383662 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Lung Cancer: Targets and Therapy, 2022-11. Verfasst von Danielle Brazel und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of California Irvine School of Medicine, Orange, CA, USA. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, University of California Irvine School of Medicine, Orange, CA, USA.
- Chao Family Comprehensive Cancer Center, Orange, CA, USA.
- St. Marianna University School of Medicine, Kawasaki, Japan.
ORCID-Profile: Misako Nagasaka
Zitieren
APA
Brazel, D., Arter, Z., & Nagasaka, M. (2022). A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib. Lung Cancer: Targets and Therapy, Volume 13, 75-80. https://doi.org/10.2147/lctt.s383662
Vancouver
Brazel D, Arter Z, Nagasaka M. A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib. Lung Cancer: Targets and Therapy. 2022;Volume 13:75-80. doi:10.2147/lctt.s383662
BibTeX
@article{Brazel2022,
author = {Brazel, Danielle and Arter, Zhaohui and Nagasaka, Misako},
title = {A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib},
journal = {Lung Cancer: Targets and Therapy},
year = {2022},
volume = {Volume 13},
pages = {75--80},
doi = {10.2147/lctt.s383662}
}
EUVIMED